23 November 2016
: Case report
Nivolumab-Induced Severe Akathisia in an Advanced Lung Cancer Patient
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Adverse events of drug therapy , Educational Purpose (only if useful for a systematic review or synthesis)
Jiro AbeBDE, Taku SatoB, Ryota TanakaB, Toshimasa OkazakiB, Satomi TakahashiBDOI: 10.12659/AJCR.900941
Am J Case Rep 2016; 17:880-882
Abstract
BACKGROUND: Nivolumab is an anti-PD-1 immune checkpoint inhibitor that was recently developed for cancer immunotherapy. In the clinical trials of nivolumab, its adverse effects were reported to be less likely than those of conventional anti-cancer agents; however, after practical clinical distribution, it has come to be known that nivolumab induces various immune-related adverse events.
CASE REPORT: A 58-year-old male with a recurrence of lung adenocarcinoma was treated with nivolumab. Only four days after the initial administration of nivolumab, the patient presented with unbearable restlessness and distress that was resistant to all therapeutic agents used, and it gradually became worse. He finally came to need deep sedation despite his cancer status being stable during the course. Clinical tests including magnetic resonance imaging, cerebrospinal fluid cytology, and antibodies of paraneoplastic syndrome exhibited no signs of encephalitis or another possible cause of the neuropathy. The diagnosis of akathisia could be made only by his somatoform presentation. It was uncertain whether or not this complication was correlated with the activation of his immune system.
CONCLUSIONS: Anti-immune check point inhibitors may induce many unknown adverse events. Severe akathisia induced by nivolumab, as in our case, has not been reported yet. Collecting every adverse event of nivolumab may be important to make a better algorithm to manage its huge variety of complications.
Keywords: Akathisia, Drug-Induced
SARS-CoV-2/COVID-19
19 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936370
17 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936651
13 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936589
13 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936574
In Press
20 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936826
19 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936252
19 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936318
19 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936377
Most Viewed Current Articles
31 Dec 1969 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
31 Dec 1969 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399
31 Dec 1969 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
31 Dec 1969 : Case report
DOI :10.12659/AJCR.935355
Am J Case Rep 2022; 23:e935355